Taxanes for the treatment of metastatic breast cancer

Breast Cancer: Basic and Clinical Research

Volumn 6, Issue 1, 2012, Pages 159-171

  Gradishar, W J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Docetaxel; Metastatic breast cancer; Nab paclitaxel; Paclitaxel; Taxanes

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DOCETAXEL; MITOMYCIN; PACLITAXEL; VINBLASTINE;

ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; EARLY CANCER; EDEMA; FEBRILE NEUTROPENIA; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; INFECTION; LEUKOPENIA; MEDICAL DECISION MAKING; NEUTROPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; RETREATMENT; REVIEW; SENSORY NEUROPATHY; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 84868598489     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.4137/BCBCR.S8205     Document Type: Review

References (86)

1. Cancer facts and figures 2012. American Cancer Society Web site. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Updated 2012. Accessed Mar 6, 2012.
2. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10 Suppl 3:20-9.
3. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100(1):44-52.
4. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Breast Cancer. version 2.2012.
5. Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer. 2005;93(3): 293-301.
6. Nowak AK, Wilcken NR, Stockler MR, Hamilton A, Ghersi D. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol. 2004;5(6):372-80.
7. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995; 332(15):1004-14.
8. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and anti-tumor agent from taxus brevifolia. J Am Chem Soc. 1971;93(9):2325-7.
9. National Cancer Institute. Success story: Taxol (NCS125973). http://dtp.nci.nih.gov/timeline/flash/success_stories/S2_taxol.htm. Accessed Jan 6, 2012.
10. Taxotere (docetaxel) [package insert]. Bridgewater, NJ: Sanofi-Aventis US. LLC; 2010.
11. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005;23(24):5542-51.
12. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst. 1991;83(4):288-91.
13. Taxol (paclitaxel) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2010.
14. US Food and Drug Administration. Taxol.Web site. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetail. Accessed Jan 06, 2012.
15. Cortazar P, Justice R, Johnson J, Sridhara R, Keegan P, Pazdur R. US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol. 2012;30(14):1705-11.
16. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996;14(6):1858-67.
17. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: A retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005; 104(8):1742-50.
18. Us Food and Drug Administration. taxotere. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed Jan 6, 2012.
19. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 study group. J Clin Oncol. 1999;17(5):1413-24.
20. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42(7):665-85.
21. Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Summit, NJ: Celgene Corporation. 2012.
22. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794-803.
23. John TA, Vogel SM, Tiruppathi C, Malik AB, Minshall RD. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol. 2003;284(1):L187-96.
24. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophorfree, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4):1317-24.
25. Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2009;2(2):59-64.
26. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release. 2000;65(1-2):271-84.
27. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387-92.
28. Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171-83.
29. Stehle G, Sinn H, Wunder A, et al. Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol. 1997;26(2):77-100.
30. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 2008;27(4):691-705.
31. Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WG. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids. 2005;72(4):267-72.
32. Jones C, Mackay A, Grigoriadis A, et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: Identification of novel prognostic markers for breast cancer. Cancer Res. 2004;64(9): 3037-45.
33. Hamilton EP, Kimmick GG, Desai N, et al. Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC). J Clin Oncol (Meeting Abstracts). 2010;28(15s): (Suppl; abstract 1109).
34. Yardley DA, Danie B, Inhorn RC, et al. SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and nab-paclitaxel (nab-P) in locally advanced breast cancer (LABC). J Clin Oncol (Meeting Abstracts). 2010;28(15):Abstract 10574.
35. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol. 2011;29(34):4548-54.
36. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991; 83(24):1797-805.
37. Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol. 1995;13(10):2575-81.
38. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001;19(22):4216-23.
39. Burris HA 3rd. Single-agent docetaxel (taxotere) in randomized phase III trials. Semin Oncol. 1999;26(3 Suppl 9):1-6.
40. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000;18(6):1212-9.
41. Valero V. Docetaxel as single-agent therapy in metastatic breast cancer: Clinical efficacy. Semin Oncol. 1997;24(4 Suppl 13):S13+11+8.
42. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leukemia group B protocol 9840. J Clin Oncol. 2008;26(10):1642-9.
43. Rivera E, Mejia JA, Arun BK, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008;112(7):1455-61.
44. Mauri D, Kamposioras K, Tsali L, et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. Cancer Treat Rev. 2010;36(1):69-74.
45. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8(5):1038-44.
46. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005;23(31): 7785-93.
47. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009;27(22): 3611-9.
48. Gradishar WJ, Krasnojon D, Cheporov S, et al. Phase II trial of nabpaclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: Final analysis of overall survival. Clin Breast Cancer. 2012. [Epub ahead of print.]
49. Mirtsching B, Cosgriff T, Harker G, Keaton M, Chidiac T, Min M. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. Clin Breast Cancer. 2011;11(2): 121-8.
50. Genetics Home Reference. BRCA1. BRCA1 Web site. http://ghr.nlm.nih.gov/gene/BRCA1. Updated 2012. Accessed July 30 2012.
51. Genetics Home Reference. BRCA2. BRCA2 Web site. http://ghr.nlm.nih.gov/gene/BRCA2. Updated 2012. Accessed Jul 30, 2012.
52. American Cancer Society. Breast cancer facts and figures 2011-2. Website of the American Cancer Society Web site. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-030975.pdf. Published 2012. Updated 2012. Accessed Mar 13, 2012.
53. Kriege M, Jager A, Hooning MJ, et al. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer. 2012;118(4):899-907.
54. Promkan M, Liu G, Patmasiriwat P, Chakrabarty S. BRCA1 suppresses the expression of survivin and promotes sensitivity to paclitaxel through the calcium sensing receptor (CaSR) in human breast cancer cells. Cell Calcium. 2011;49(2):79-88.
55. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle. 2006;5(9):1001-7.
56. Bernard-Marty C, Treilleux I, Dumontet C, et al. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: Results of a pilot study. Clin Breast Cancer. 2002;3(5): 341-5.
57. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: Molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003;3(1):1-19.
58. Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol. 2007;18 Suppl 12:15-20.
59. Genetics Home Reference. ABCB1. ABCB1 Web site. http://ghr.nlm.nih.gov/gene/ABCB1. Updated 2012. Accessed Jul 30, 2012.
60. Schneider BP, Li L, Miller K, et al. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. J Clin Oncol (Meeting Abstracts). 2011;29:Abstract 1000.
61. Sissung TM, Mross K, Steinberg SM, et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer. 2006;42(17):2893-6.
62. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007;4(4): 44-51.
63. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814): 432-44.
64. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol. 2002;20(6):1456-66.
65. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275-92.
66. Rivera E. Management of metastatic breast cancer: Monotherapy options for patients resistant to anthracyclines and taxanes. Am J Clin Oncol. 2010; 33(2):176-85.
67. Xeloda (capecitabine) [package insert]. South San Francisco, CA: Genentech; 2009.
68. Fornier MN. Approved agents for metastatic breast cancer. Semin Oncol. 2011;38 Suppl 2:S3-10.
69. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17(2):485-93.
70. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92(7):1759-68.
71. Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase II study of oral capecitabine (xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol. 2003;14(8):1227-33.
72. Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I. Oral capecitabine in anthracyclineand taxane-pretreated advanced/metastatic breast cancer. Acta Oncol. 2004;43(2):186-9.
73. Ixempra (ixabepilone) [package insert]. Princeton, NJ: Bristol-Meyers Squibb; 2011.
74. Halaven (eribulin mesylate) [package insert]. Woodcliff Lake, NJ: Eisai Incorporated; 2010.
75. Lin YC, Chang HK, Wang CH, Chen JS, Liaw CC. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: Partial cross-resistance between paclitaxel and docetaxel. Anticancer Drugs. 2000;11(8):617-21.
76. Sawaki M, Ito Y, Hashimoto D, et al. Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: A single-center study. Tumori. 2004;90(1):36-9.
77. Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998;16(10):3362-8.
78. Guo X, Loibl S, Untch M, et al. Re-challenging taxanes in recurrent breast cancer in patients treated with (neo-)adjuvant taxane-based therapy. Breast Care (Basel). 2011;6(4):279-83.
79. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210-7.
80. Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents: Occurrence and management approach. Clin Breast Cancer. 2011; 11(2):73-81.
81. Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albuminbound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2007;7(11):850-6.
82. Im A, Brufsky A, Reeder JG, Rosenweig MQ, Jung SY. Repeat use of chemotherapy in metastatic breast cancer. J Clin Oncol (Meeting Abstracts). 2011;29 [abstract 1088].
83. Pippen J, Paul D, Vukelja S, Clawson A, Iglesias J. Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer. Breast Cancer Res Treat. 2011. [Epub ahead of print.]
84. Robert N, Krekow L, Stokoe C, Clawson A, Iglesias J, O'Shaughnessy J. Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: A pilot study. Breast Cancer Res Treat. 2011;125(1):115-20.
85. Yardley DA, Raefsky E, Castillo R, et al. Results of a multicenter pilot study of weekly nab paclitaxel, carboplatin with bevacizumab and trastuzumab as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlatives. J Clin Oncol (Meeting Abstracts). 2009;27(15) [abstract 527].
86. Yardley D, Burris H 3rd, Peacock N, et al. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with t{stroke}rastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. Breast Cancer Res Treat. 2010;123(2):471-5.